ES2612889T3 - Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos - Google Patents

Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos Download PDF

Info

Publication number
ES2612889T3
ES2612889T3 ES09796016.5T ES09796016T ES2612889T3 ES 2612889 T3 ES2612889 T3 ES 2612889T3 ES 09796016 T ES09796016 T ES 09796016T ES 2612889 T3 ES2612889 T3 ES 2612889T3
Authority
ES
Spain
Prior art keywords
cells
metastasis
oncolytic adenoviral
region
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09796016.5T
Other languages
English (en)
Spanish (es)
Inventor
Akseli Hemminki
Anna Kanerva
Vincenzo Cerullo
Sari Pesonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targovax Oy
Original Assignee
Targovax Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20080671A external-priority patent/FI20080671A0/fi
Application filed by Targovax Oy filed Critical Targovax Oy
Application granted granted Critical
Publication of ES2612889T3 publication Critical patent/ES2612889T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES09796016.5T 2008-12-22 2009-12-21 Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos Active ES2612889T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FI20080671 2008-12-22
FI20080671A FI20080671A0 (fi) 2008-12-22 2008-12-22 Onkolyyttiset virukset
FI20095466A FI121508B (fi) 2008-12-22 2009-04-27 Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
FI20095466 2009-04-27
US58597109A 2009-09-29 2009-09-29
US585971 2009-09-29
PCT/FI2009/051025 WO2010072900A1 (en) 2008-12-22 2009-12-21 Oncolytic adenoviral vectors and methods and uses related thereto

Publications (1)

Publication Number Publication Date
ES2612889T3 true ES2612889T3 (es) 2017-05-19

Family

ID=44502296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09796016.5T Active ES2612889T3 (es) 2008-12-22 2009-12-21 Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos

Country Status (20)

Country Link
EP (1) EP2379586B1 (enExample)
JP (2) JP2012513209A (enExample)
KR (1) KR101761094B1 (enExample)
CN (1) CN102264760B (enExample)
AU (1) AU2009332883B2 (enExample)
BR (1) BRPI0924123B8 (enExample)
CA (1) CA2748180C (enExample)
CY (1) CY1120039T1 (enExample)
DK (1) DK2379586T3 (enExample)
ES (1) ES2612889T3 (enExample)
HR (1) HRP20170165T1 (enExample)
HU (1) HUE031689T2 (enExample)
LT (1) LT2379586T (enExample)
PL (1) PL2379586T3 (enExample)
PT (1) PT2379586T (enExample)
RU (1) RU2520823C2 (enExample)
SG (1) SG173432A1 (enExample)
SI (1) SI2379586T1 (enExample)
WO (1) WO2010072900A1 (enExample)
ZA (1) ZA201104224B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070440A2 (en) 2009-12-10 2011-06-16 Ottawa Hospital Research Institute Oncolytic rhabdovirus
BR112013006699A2 (pt) * 2010-09-24 2016-06-14 Oncos Therapeutics Oy vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
EP2619224A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
JP2016513115A (ja) 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
DK3461491T3 (da) 2013-04-18 2025-02-03 Tilt Biotherapeutics Oy Forbedret adoptiv celleterapi
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途
FI127460B (en) 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
ES3041500T3 (en) 2016-03-10 2025-11-12 Cg Oncology Inc Methods of treating solid tumors by combination therapy
LT3293201T (lt) 2016-09-12 2021-03-25 Targovax Oy Adenoviruso ir kontrolinio taško inhibitoriaus derinys vėžio gydymui
US20190275092A1 (en) * 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
AU2018206304A1 (en) * 2017-01-06 2019-07-04 Stabilitech Biopharma Ltd Virus
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
JP7260173B2 (ja) 2017-04-21 2023-04-18 ベイラー カレッジ オブ メディスン 腫瘍溶解性ウイルス療法および免疫療法
BR112019024656A2 (pt) 2017-05-25 2020-06-09 Univ Central Florida Res Found Inc vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
WO2019093435A1 (ja) * 2017-11-08 2019-05-16 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
EP3725323A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
EP3725888A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase
EP3725322A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing granzyme and perforin
KR102601875B1 (ko) * 2020-03-25 2023-11-14 (주)큐리진 면역 회피성 항종양 아데노바이러스
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
CN118853767A (zh) * 2024-08-22 2024-10-29 华中科技大学同济医学院附属同济医院 一种新型溶瘤腺病毒载体及其构建方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454445T1 (de) * 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
AU5464000A (en) * 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US20020045264A1 (en) * 2000-03-14 2002-04-18 During Matthew J. Production of chimeric capsid vectors
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
ES2276623B1 (es) * 2005-12-12 2008-06-01 Proyecto De Biomedicina Cima, S.L Nuevos adenovirus recombinantes de replicacion condicionada (crad).
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus

Also Published As

Publication number Publication date
JP2016019530A (ja) 2016-02-04
CA2748180A1 (en) 2010-07-01
KR20110096579A (ko) 2011-08-30
BRPI0924123B1 (pt) 2020-10-20
LT2379586T (lt) 2017-03-10
CA2748180C (en) 2017-06-20
CY1120039T1 (el) 2018-12-12
RU2520823C2 (ru) 2014-06-27
CN102264760B (zh) 2017-03-22
DK2379586T3 (en) 2017-02-06
EP2379586A1 (en) 2011-10-26
HRP20170165T1 (hr) 2017-04-07
CN102264760A (zh) 2011-11-30
AU2009332883A1 (en) 2011-07-07
BRPI0924123B8 (pt) 2021-05-25
HUE031689T2 (en) 2017-07-28
KR101761094B1 (ko) 2017-08-04
AU2009332883B2 (en) 2015-05-21
JP6280084B2 (ja) 2018-02-14
SI2379586T1 (sl) 2017-02-28
SG173432A1 (en) 2011-09-29
ZA201104224B (en) 2012-09-26
EP2379586B1 (en) 2016-11-02
JP2012513209A (ja) 2012-06-14
WO2010072900A1 (en) 2010-07-01
RU2011130511A (ru) 2013-01-27
PT2379586T (pt) 2017-02-09
PL2379586T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
JP7564572B2 (ja) 単離された組換え体腫瘍溶解性ワクシニアウイルスとｎｋ細胞を含む治療薬、その使用およびそれを適用したキット
CN105671083B (zh) PD‑1基因重组病毒质粒及构建、重组逆转录病毒Lenti‑PD‑1‑Puro及包装与应用
Marcial et al. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality:(preliminary report) by the Radiation Therapy Oncology Group (RTOG)
Freeman et al. The Treatment of Ovarian Cancer with a Gene Modified Cancer Vaccine: A Phase I Study. Tulane University, New Orleans, Louisiana
EP3566709B1 (en) Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancers
Bokemeyer et al. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy
CN106974938A (zh) 一种具有抗肝癌作用的骨髓间充质干细胞来源的外泌体及其药物制剂
Wang et al. Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC)
TWI439275B (zh) 一種人類自然殺手細胞之體外增殖方法
WO2021135984A1 (zh) 一种有限代数的滋养细胞的制备方法、snk细胞的培养方法和治疗肿瘤的方法
CN111000851B (zh) 丹参酮i在制备肿瘤细胞自噬诱导剂药物中的应用
Fujisawa et al. Adjuvant immunotherapy of primary resected lung cancer with transfer factor
CN103127055A (zh) 桔皮素作为制备治疗实体瘤化疗药物增敏剂的应用
CN112661846A (zh) 一种靶向tshr的复制缺陷性重组慢病毒car-t转基因载体、其构建方法及其应用
CN110205293A (zh) 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用
CN116712447A (zh) 淫羊藿苷在微卫星稳定型肿瘤中的应用
CN111939262A (zh) 一种治疗肿瘤或癌症的药物组合物和其应用
Rai et al. A rare case of a high-grade thymic squamous cell carcinoma presenting as cardiac tamponade
CN109453392A (zh) 纹蛋白互作蛋白抑制剂及其在制备抗肿瘤药物中的用途
CN115350176A (zh) 一种胃癌肿瘤细胞和胃癌肿瘤干细胞治疗药物及其应用
CN118436669A (zh) 一种抗胰腺癌肿瘤药物组合物及其应用
RU2348420C2 (ru) Способ лечения местно-распространенного рака легкого
HK40106046A (zh) 治疗剂、药盒、分离的重组溶瘤痘病毒在治疗肿瘤和/或癌症的药物中的用途
CN107693790A (zh) 用于肺癌治疗的联合药物
De Sande et al. P-537 Cisplatin plus gemcitabine with or without vinorelbine as neoadjuvant therapy for radically-treatable stage II non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (grupo Oncológico del Norte de Espan˜ a)